|
|
Volumn 98, Issue 11, 2006, Pages 733-735
|
|
Raloxifene prevails in STAR trial, may face easier road to acceptance than previous drugs.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;
RALOXIFENE;
SELECTIVE ESTROGEN RECEPTOR MODULATOR;
TAMOXIFEN;
ARTICLE;
BREAST TUMOR;
CATARACT;
CHEMICALLY INDUCED DISORDER;
CONTROLLED CLINICAL TRIAL;
DRUG APPROVAL;
DRUG CONTRAINDICATION;
ECONOMICS;
FEMALE;
FOOD AND DRUG ADMINISTRATION;
HOT FLUSH;
HUMAN;
OSTEOPOROSIS;
POSTMENOPAUSE;
RISK FACTOR;
THROMBOEMBOLISM;
TREATMENT OUTCOME;
UNITED STATES;
UTERUS CANCER;
ANTINEOPLASTIC AGENTS, HORMONAL;
BREAST NEOPLASMS;
CATARACT;
CONTROLLED CLINICAL TRIALS;
DRUG APPROVAL;
ESTROGEN RECEPTOR MODULATORS;
FEMALE;
HOT FLASHES;
HUMANS;
OSTEOPOROSIS;
POSTMENOPAUSE;
RALOXIFENE;
RISK FACTORS;
TAMOXIFEN;
THROMBOEMBOLISM;
TREATMENT OUTCOME;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
UTERINE NEOPLASMS;
|
|
EID: 33745282112
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djj253 Document Type: Article |
|
Times cited : (5)
|
|
References (0)
|
